Differences between Tumor Necrosis Factor-Alpha Levels and Interleukin-2 Levels in people with schizophrenia who get risperidone drugs in the acute phase of treatment in the Prof. DR. M. Ildrem Psychiatric Hospital, Medan

Muhammad Hasbi; Bahagia Loebis; Vita Camellia; Elmeida Effendy

doi:10.3889/oamjms.2021.6316

Authors

Muhammad Hasbi Department of Psychiatry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Bahagia Loebis Department of Psychiatry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Vita Camellia Department of Psychiatry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia https://orcid.org/0000-0001-5774-3276
Elmeida Effendy Department of Psychiatry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2021.6316

Keywords:

Schizophrenia, Tumor necrosis factor-α levels, Interleukin-2 levels, Acute phase of treatment

Abstract

Background: We looked for differences between Tumor Necrosis Factor – Alpha and Interleukin-2 levels in people with schizophrenia who got risperidone medication in the acute phase of treatment at Prof.DR.M.Ildrem psychiatric hospital Medan. Methods: We conducted a cross-sectional study that included 40 subjects. This study is a numerical comparative analytical study not paired with a single measurement with subject retrieval performed in a non-probability sampling method of consecutive sampling type. Results: The analysis test results showed Median levels of TNF-α in the group of people with schizophrenia were obtained at 3.40 with a minimum score of 0.65 and with a maximum score of 43.8 while in the healthy control group the median score of TNF-α levels was 14.75 with a minimum score of 5.18 and a maximum score of 31.1. The average IL-2 level in people with schizophrenia was found at 5.26 with a standard deviation of ±0.987 and at the control was obtained at 3.43 with a standard deviation ± 0.665. Conclusions: There is a significant difference in TNF-α levels between groups of people with schizophrenia who get risperidone 4 mg in the acute phase of treatment and control. There was a significant difference between IL-2 levels between people with schizophrenia who got risperidone 4 mg in the acute phase of treatment and control.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Scizophrenia; 2019. Available from: https://www.who.int/news/room/facts/sheetsdetail/schizophrenia. [Last accessed on 2019 Oct 04].

Han Meng LV, Tan YL, Yan SX, Tian L, Chen DC, Tan SP et al. Decreased Serum TNF-Alpha Levels in Chronic Schizophrenia Patients on-Term Antiosyccotics: Correlation with Psychopathology and Cognition; 2015.

Ajami A, Navaei ZA, Zossaeni ZH, Taghipour M. Serum TNF-alpha,IL-10, and IL-2 in Schizopherenic Patients before and after Treatment with Risperidone and Clozapine. Baqiyatallah University of medical Science; 2014.

Xiu MH, Man LJ, Wang D, Du X, Du X, Yin G, et al. Tumor necrosis factor-alpha-1031T/c polymorphism is associated with cognitive deficits in chronic schizophrenia patients versus healthy controls. Am J Med Genet B Neuropsychiatr Genet. 2018;177(4):379-87. https://doi.org/10.1002/ajmg.b.32622 PMid:29633506 DOI: https://doi.org/10.1002/ajmg.b.32622

Tan Y, Li Y, Tan S, Wang Z, Yang FD, Cao B, et al. Increased interleukin-2 serum levels were associated with psychopathological symptoms and cognitive deficits in treatment resistent schizophrenia. Schizophr Res. 2015;169(1-3):16-21. https://doi.org/10.1016/j.schres.2015.10.038 PMid:26549630 DOI: https://doi.org/10.1016/j.schres.2015.10.038

Sadock BJ, Sadock VA, Ruiz P. Schizophrenia spectrum and other Psychotic Disorder. In: Kaplan and Sadock’s Synopsis of Psychiatry Behavioural Sciences/Clinical Psychiatry. 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2015. p. 300-23. https://doi.org/10.1017/s0033291700033304 DOI: https://doi.org/10.1017/S0033291700033304

Bowmans C, Sonneville CD, Mulder CL, van Roijen LH. Employment and the associated impact on quality of life in people diagnosed with schizophrenia. Neuropsychiatr Dis Treat. 2015;11:2125-42. https://doi.org/10.2147/ndt.s83546 PMid:26316759 DOI: https://doi.org/10.2147/NDT.S83546

Huang J, Chiovenda A, Shao Y, Ma H, Li H, Good MJ. Low level of knowledge regarding diagnosis and treatment among inpatients with schizophrenia in shanghai. Neuropsychiatr Dis Treat. 2018;14(1):185-91. https://doi.org/10.2147/ndt.s152917 PMid:29379291 DOI: https://doi.org/10.2147/NDT.S152917

Phinho LG, Pereira A, Chaves C. Influence of sociodemographic and clinical characteristics on the quality of life of Patients with schizophrenia. Rev Esc Enferm USP. 2017;51:e03244. https://doi.org/10.1590/s1980-220x2016031903244 PMid:28902324 DOI: https://doi.org/10.1590/s1980-220x2016031903244

Juncal-Ruiz M, Riesco-Dávila L, de la Foz VO, Ramírez-Bonilla M, Martínez-García O, Irure-Ventura J, et al. The effect of excess weight on circulating inflammatory cytokines in drug naïve first episode psychosis individuals. J Neuroinflammation. 2018;15(1):63. https://doi.org/10.1186/s12974-018-1096-6 PMid:29490673 DOI: https://doi.org/10.1186/s12974-018-1096-6

Zhang XY, Zhou DF, Zhang PY, Gui YW, Cao LY, Shen YC. Elevated Interleukin-2, Interleukin-6, and Interleukin-8 Serum Levels in Neuroleptic-free Schizophrenia: Association with Psychopathology, Beijing Medical University; 2002. https://doi.org/10.1016/s0920-9964(01)00296-1 DOI: https://doi.org/10.1016/S0920-9964(01)00296-1